Name

Next&Bio

Legal name

Next&Bio Inc.

Website

https://nextandbio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Organoid-based Drug Screening & Precision Medicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

Keywords

• Organoid drug screening
• Precision medicine platform
• Patient-derived organoids
• Organ-on-a-chip technology
• Anticancer drug evaluation

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Organoid Library Sales & Distribution: Sale of patient-derived organoids (PDOs) to researchers and pharmaceutical companies for disease modeling and drug development. NEXT&BIO offers organoids from lung, colon, breast, and other cancer types with integrated genomic profiles. Organoid bank services for hospitals and research institutions.
2. Drug Efficacy Evaluation Services (POINT™ Platform): Patient-specific anticancer drug sensitivity testing using patient-derived organoids. Services provided to pharmaceutical companies for drug candidate validation and to hospitals for clinical decision support. Revenue from contract research and testing fees.
3. Brain Organoid and CNS Disease Modeling Services: HTS-scale brain organoid screening services for neurodegenerative disease drug development. Revenue from research service contracts with biotech and pharmaceutical companies (e.g., Sovargen for brain disease drug efficacy evaluation).
4. iMag™ Nucleic Acid Extraction Kit Sales: Sales of iMag™ nucleic acid extraction reagent kits for organoid quality verification. Sales and distribution rights licensed to Woongbee Meditech (웅비메디텍). Eight product types covering cell, blood, and tissue samples.
5. Technology Licensing (HUB Organoids): Inbound technology licensing from HUB (Netherlands) for all organ types combined with outbound sublicensing and technology sharing capabilities.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Next&Bio builds and operates an organoid-based precision medicine platform that produces standardized patient-derived organoids (PDOs) and provides drug efficacy evaluation services. Its core offerings include the POINT™ drug sensitivity testing platform, an integrated organoid library with genomic profiles, the Miniature Brain Array for high-throughput CNS drug screening, and MPS (Microphysiological System) organ-on-a-chip technology. The company sells organoids, reagents, and AI image-analysis software to pharmaceutical companies, hospitals, and academic research institutions.

Product overview

Next&Bio is an organoid-based precision medicine platform company offering standardized organoid production and drug evaluation services. The core portfolio consists of the POINT™ drug efficacy evaluation platform, an Organoid Library and Bank System with integrated genomic data, and the Miniature Brain Array™ for HTS-scale brain disease drug screening. The technology suite includes MPS (Microphysiological System) organ-on-a-chip technology and iMag™ nucleic acid extraction kits for quality control. VONet AI software enables 3D organoid structure prediction. The company targets pharmaceutical companies for drug development services and hospitals for clinical precision medicine applications.

Differentiator

Problem solved

Functional benefit

Brands

• POINT™: 오가노이드 기반 약물 유효성 평가 플랫폼 - Patient-derived Organoid for Individualized Therapeutics
• Miniature Brain Array™
• VONet

Products and services

• POINT™ Drug Efficacy Evaluation Platform Organoid-based drug efficacy evaluation platform that tests anticancer drug sensitivity on patient-derived organoids. Uses standardized 3D culture techniques and high-throughput analysis to select optimal drugs for individual patients. For pharmaceutical companies, hospitals, and oncologists.
• Organoid Library Patient-derived organoid library integrating genomic profile information. Contains lung, colon, breast, and other cancer organoids with genetic mutation data for research and drug screening applications. The first organoid library in Korea. For researchers and pharmaceutical companies.
• Organoid Bank System Organoid banking infrastructure with global-standard SOPs for quality assurance, integrated server for data analysis, and security. Near 400 organoid lines from various organs derived from different patients. For hospitals and research institutions.
• Miniature Brain Array™ High-throughput screening platform using 384 or 768 miniature brains arrayed in 96-well plates. Each plate contains uniform miniature brains suitable for bioimaging analysis and drug screening. For biotech and pharmaceutical companies developing CNS disease drugs.
• MPS (Microphysiological System) / Organ-on-a-Chip Organ-on-a-chip technology implementing human tissue environment using tissue chips, combining microfluidic chip technology with tissue engineering. Solves organoid inhomogeneity through ultra-precise design. For drug development and cell therapy preclinical evaluation.
• iMag™ Nucleic Acid Extraction Reagent Kit Magnetic nano bead-based nucleic acid extraction reagent kit for organoid quality verification. 8 product types (tube, bottle, plate formats) for cell, blood, and tissue samples. Class 1 medical device approved by MFDS. Sales rights licensed to Woongbee Meditech.
• VONet AI Software Deep learning AI software for organoid 3D structure prediction and analysis. Analyzes minimal confocal microscopy images (minimum 11 vs. 60+ traditional) to predict and render 3D organoid architecture, reducing imaging time by 6x.

Quantifiable outcome

• Organoid imaging analysis time reduced by 6x using VONet AI (from ~60 images to 11 images)
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

13 partnerships are on record, tiered core, minor and major.

• Cancer Science Institute of Singapore (CSI) / National University of Singapore (NUS)coreStrategic or Co-development Partner · 30 July 2025Joint organoid research center establishment agreement. Plans to build world's largest Asian patient-derived organoid library from Chinese, Indian, Malay, and other Asian cancer patients in Singapore. Joint preclinical evaluation platform development. Prof. Ashok Venkitaraman (NUS Distinguished Professor) leads research. Next&Bio to deploy organoid research personnel to Singapore.
• GC Cell (지씨셀)coreStrategic or Co-development Partner · 11 June 2025Joint development of cell therapy preclinical evaluation platform using patient-derived organoids and MPS (Microphysiological System) for CAR-NK cell therapy efficacy testing against intractable solid tumors. Part of Ministry of Health and Welfare national project 'Advanced Biopharmaceutical Nonclinical Efficacy Evaluation Technology Development based on Microphysiological System.'
• Amplia Therapeutics Limited (호주)coreStrategic or Co-development Partner · 13 November 2024Joint research contract for pancreatic cancer drug development. Next&Bio creates organoids from KRAS-mutated pancreatic cancer patient tissue and evaluates Amplia's drug candidate narmafotinib (AMP945, FAK inhibitor). First collaboration with a global pharmaceutical company leveraging Next&Bio's organoid technology.
• CytoZen (싸이토젠)minorStrategic or Co-development Partner · 5 April 2024Business agreement for CTC (Circulating Tumor Cell)-based organoid production. CytoZen separates intact live CTCs from blood using proprietary technology; Next&Bio cultures them into organoids for anticancer drug sensitivity testing and metastasis research.
• Sovargen (소바젠)minorStrategic or Co-development Partner · 28 February 2024Research service contract for brain organoid-based drug efficacy evaluation of Sovargen's intractable brain disease treatments (epilepsy, glioblastoma, Alzheimer's). Next&Bio uses iPSC-derived brain organoids for evaluation.
• KTR (한국화학융합시험연구원)coreStrategic or Co-development Partner · 13 October 2023Three-way MOU with Kolmar Korea and KTR for advanced alternative test service platform development. Development of OECD TG-compliant alternative testing service platform using 3D in vitro culture technology for cosmetics and pharmaceutical safety assessment.
• L-Base (엘베이스)minorStrategic or Co-development Partner · 19 September 2023Joint research for new drug development using lung and colorectal cancer patient-derived organoids to evaluate anticancer drug candidate LB217 efficacy. L-Base plans to file IND application with UK MHRA based on results.
• Chonnam National University Hwasun Hospital (화순전남대학교병원)majorStrategic or Co-development Partner · 23 April 2023MOU for co-establishment of organoid bank. Plans to systematically store organoids from various cancer types and organs for precision medicine and regenerative medicine research. Joint research with cardiologist Prof. Ahn Young-geun on organoid-based regenerative therapy.
• Korea University Anam Hospital (고려대학교 안암병원)majorStrategic or Co-development Partner · 23 April 2023Joint research agreement for organoid-based precision medicine and personalized drug screening. Collaboration on cancer organoid research, process development for precision medicine, and co-development of personalized cancer treatment.
• Myongji Hospital (명지병원)majorStrategic or Co-development Partner · 23 April 2023MOU for co-establishment of organoid bank. Focus on liver, stomach, colorectal, and pancreatic cancer organoids for personalized precision medicine services.
• KIST Europe (한국과학기술연구원 유럽연구소)coreStrategic or Co-development Partner · 11 July 2022Joint research agreement for OECD AOP (Adverse Outcome Pathway) guideline registration using organoid-based animal replacement test methods. Established protocols for liver and lung disease AOP models; registered as OECD development project in June 2022.
• HUB Organoids (네덜란드)coreTechnology or Integration · 1 January 2021Technology licensing agreement — secured usage rights for all organ types (colon, pancreas, kidney, liver, stomach, lung, ovary) from HUB, the company that pioneered organoid technology under Hans Clevers. Includes technology sharing provisions.
• Nexel (넥셀)minorGTM or Marketing Partner · 1 January 2021Co-marketing agreement for drug screening services. Collaborative marketing to pharmaceutical companies and research institutions for organoid-based drug screening offerings.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• HUB Organoids: Pioneer of patient-derived organoid technology (founded by Hans Clevers). Next&Bio holds an inbound technology licensing agreement with HUB covering all organ types — they share the same core platform and target pharma R&D customers, making HUB both a licensor and the most direct functional peer.
• Crown Bioscience: Global preclinical CRO with extensive patient-derived xenograft (PDX) and increasingly organoid-based oncology services. Comparable to Next&Bio in serving pharma drug-efficacy evaluation, but at materially larger scale with global infrastructure.
• MIMETAS: Dutch organ-on-a-chip / MPS company offering microfluidic 3D tissue models for drug screening. Direct technology overlap with Next&Bio's MPS offering and shared target market of pharma preclinical development.
• CN Bio: UK-based organ-on-chip / MPS company with single- and multi-organ microphysiological systems used by pharma for ADME/toxicology studies. Comparable to Next&Bio's MPS platform and drug-evaluation service offering.
• Emulate: US organ-on-chip platform company using microfluidic chips to model human organ physiology for pharma and cosmetics safety testing. Comparable in MPS technology and animal-replacement positioning, including OECD-relevant submissions.
• InSphero: Swiss 3D cell-culture and organoid company providing in vitro disease models and toxicology services for pharma. Shares Next&Bio's HTS drug-screening business model and target customer base.

Emerging players

• Curi Bio: Seattle-based company combining iPSC-derived cells, organoids, and MPS platforms for drug discovery and safety assessment. Partial overlap with Next&Bio's brain organoid and MPS offering, though at earlier commercialization stage.
• DefiniGEN: UK iPSC-derived organoid company providing liver, pancreatic, and intestinal disease models. Comparable in iPSC-derived organoid technology with Next&Bio's standardized organoid production approach.
• Newcells Biotech: UK-based organoid and iPSC-derived tissue model company with focus on kidney, liver, retina, and lung models for pharma. Adjacent technology overlap with Next&Bio's organoid portfolio.
• Prellis Biologics: US-based company using 3D-printed lymph node organoids and human tissue models for antibody discovery and therapeutic development. Technology-adjacent to Next&Bio's organoid focus, particularly in producing standardized 3D biological structures.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Next&Bio